Granisetron 2.0: The Advent of Subcutaneous Extended-Release Formulation and Precision Dosing
-
BY Saundra Seaton
- July 21, 2026 4:57 pm
- no comment
The management of chemotherapy-induced nausea and vomiting (CINV) has been revolutionized by the introduction of 5-HT3 receptor antagonists, with granisetron long established as a cornerstone of antiemetic prophylaxis. For decades, the therapeutic arsenal consisted of oral tablets, intravenous (IV) infusions, and a transdermal patch. While effective, these modalities present limitations in convenience, compliance, and pharmacokinetic […]